Association of metformin use with Alzheimer’s disease in patients with newly diagnosed type 2 diabetes: a population-based nested case–control study
Open Access
- 15 December 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Abstract
Metformin reduces insulin resistance, which constitutes a pathophysiological connection of diabetes with Alzheimer’s disease (AD), but the evidence of metformin on AD development was still insufficient and conflicting. We investigated AD risk in patients with newly diagnosed type 2 DM treated with metformin. This retrospective, observational, nested case–control study included patients with newly diagnosed type 2 DM obtained from the Korean National Health Insurance Service DM cohort (2002–2017). Among 70,499 dementia-free DM patients, 1675 AD cases were matched to 8375 controls for age, sex, and DM onset and duration. The association between AD and metformin was analyzed by multivariable regression analyses, adjusted for comorbidities and cardiometabolic risk profile. Metformin use was associated with an increased odds of AD (adjusted odds ratio [AOR] 1.50; 95% CI 1.23–1.83). The risk of AD was higher in patients with a longer DM duration. Furthermore, AD risk was significantly high in DM patients with depression (AOR 2.05; 95% CI 1.02–4.12). Given the large number of patients with DM who are taking metformin worldwide, a double-blinded, prospective study is required to determine the long-term cognitive safety of metformin.Keywords
All Related Versions
Funding Information
- This study was supported by a research grant from the Korean Association for Geriatric Psychiatry and a Faculty Research Grant from Yonsei University College of Medicine. (6-2018-0171, 6-2018-0171, 6-2018-0171)
This publication has 38 references indexed in Scilit:
- Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer's Disease: A Population‐Based Case–Control StudyJournal of the American Geriatrics Society, 2012
- Insulin resistance and hippocampal volume in women at risk for Alzheimer's diseaseNeurobiology of Aging, 2011
- Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changesNeuropharmacology, 2011
- Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signalingProceedings of the National Academy of Sciences, 2010
- AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathiesActa Neuropathologica, 2010
- Antidiabetic drug metformin (Glucophage R ) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcriptionProceedings of the National Academy of Sciences, 2009
- Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins.Psychology and Aging, 2009
- Increased Glucose Levels Are Associated With Episodic Memory in Nondiabetic WomenDiabetes, 2008
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Is Depression a Risk Factor for Dementia or Cognitive Decline?Gerontology, 2000